|
Glasgow Precision Oncology Laboratory
The University of Glasgow's Glasgow Precision Oncology Laboratory (GPOL) is a molecular research facility that partners with the NHS and industry to perform research into the development of novel therapeutic strategies, the creation of pan-cancer genomic assays and provide knowledge transfer for healthcare systems to enable them to develop landscapes for therapeutic testing in cancer. GPOL's integrated structure is designed to take scientific ideas through preclinical studies to translation into the clinic. GPOL combines research expertise in targeted capture and whole-genome sequencing, cancer bioinformatics and the development of patient pathways in precision oncology in routine healthcare. GPOL performs tests for discovery work on patient tumours, including whole-genome sequencing and RNA-seq, and experiments to understand models of disease, particularly genetically engineered mouse models, by defining their genomic mutational landscapes and transcriptome, and providin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
University Of Glasgow
, image = UofG Coat of Arms.png , image_size = 150px , caption = Coat of arms Flag , latin_name = Universitas Glasguensis , motto = la, Via, Veritas, Vita , mottoeng = The Way, The Truth, The Life , established = , type = Public research university Ancient university , endowment = £225.2 million , budget = £809.4 million , rector = Rita Rae, Lady Rae , chancellor = Dame Katherine Grainger , principal = Sir Anton Muscatelli , academic_staff = 4,680 (2020) , administrative_staff = 4,003 , students = () , undergrad = () , postgrad = () , city = Glasgow , country = Scotland, UK , colours = , website = , logo ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Genetically Modified Mouse
A genetically modified mouse or genetically engineered mouse model (GEMM) is a mouse (''Mus musculus'') that has had its genome altered through the use of genetic engineering techniques. Genetically modified mice are commonly used for research or as animal models of human diseases, and are also used for research on genes. Together with patient-derived xenografts (PDXs), GEMMs are the most common ''in vivo'' models in cancer research. Both approaches are considered complementary and may be used to recapitulate different aspects of disease. GEMMs are also of great interest for drug development, as they facilitate target validation and the study of response, resistance, toxicity and pharmacodynamics. History In 1974 Beatrice Mintz and Rudolf Jaenisch created the first genetically modified animal by inserting a DNA virus into an early-stage mouse embryo and showing that the inserted genes were present in every cell. However, the mice did not pass the transgene to their offspring, and th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cancer Organisations Based In The United Kingdom
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other causes. Over 100 types of cancers affect humans. Tobacco use is the cause of about 22% of cancer deaths. Another 10% are due to obesity, poor diet, lack of physical activity or excessive drinking of alcohol. Other factors include certain infections, exposure to ionizing radiation, and environmental pollutants. In the developing world, 15% of cancers are due to infections such as ''Helicobacter pylori'', hepatitis B, hepatitis C, human papillomavirus infection, Epstein–Barr virus and human immunodeficiency virus (HIV). These factors act, at least partly, by changing the genes of a cell. T ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cancer Genomics
Oncogenomics is a sub-field of genomics that characterizes cancer-associated genes. It focuses on genomic, epigenomic and transcript alterations in cancer. Cancer is a genetic disease caused by accumulation of DNA mutations and epigenetic alterations leading to unrestrained cell proliferation and neoplasm formation. The goal of oncogenomics is to identify new oncogenes or tumor suppressor genes that may provide new insights into cancer diagnosis, predicting clinical outcome of cancers and new targets for cancer therapies. The success of targeted cancer therapies such as Gleevec, Herceptin and Avastin raised the hope for oncogenomics to elucidate new targets for cancer treatment. Besides understanding the underlying genetic mechanisms that initiate or drive cancer progression, oncogenomics targets personalized cancer treatment. Cancer develops due to DNA mutations and epigenetic alterations that accumulate randomly. Identifying and targeting the mutations in an individual patien ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
The Beatson Institute For Cancer Research
The Beatson Institute for Cancer Research (also known as the Cancer Research UK Beatson Institute) is a biological research facility that conducts research into the basic biology of cancer. It is based in Glasgow, Scotland. The Institute is named in recognition of Sir George Beatson, a surgeon, who in 1912 established a research department in the cancer hospital in Glasgow. This department became independent from the hospital in 1967 when the Institute was founded by the then Director, Dr John Paul. Dr Paul raised sufficient funds to move the Beatson in 1976 to its present location on the Garscube Estate, where it has since interacted closely with researchers at the University of Glasgow. The Institute moved in 2008 to a new research building built by Reiach and Hall Architects. Professor John Wyke became Director in 1987, Professor Karen Vousden in 2002 and Professor Owen Sansom in 2017. Research groups at the Beatson Institute study cancer initiation, metabolism and metasta ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Andrew Biankin
Andrew Victor Biankin is a Scotland-based Australian clinician-scientist, best known for his work on enabling precision oncology in learning healthcare systems by integrating discovery, preclinical and clinical development to accelerate novel therapeutic strategies, and developing standardised pan-cancer assays for use by healthcare systems and researchers worldwide. Biankin, who works as the Regius Professor of Surgery at the University of Glasgow, was made an Officer of the Order of Australia (AO) in the Queen’s Birthday Honours List for 2019, for distinguished service to medical research, and to the treatment of pancreatic cancer, as a clinician-scientist. Biankin is a Fellow of the Royal Society of Edinburgh and a Fellow of the Academy of Medical Sciences. He has written over 160 articles in major medical journals relating to cancer, genomics and precision medicine. Early history The eldest of three sons, Biankin was born in Sydney’s western suburbs where his im ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Physician-scientist
A physician-scientist is traditionally a holder of a medical degree and a doctor of philosophy also known as an MD-PhD. Compared to other clinicians, physician-scientists invest significant time and professional effort in scientific research and spend correspondingly less time in direct clinical practice with ratios of research to clinical time ranging from 50/50 to 80/20. Physician-scientists are often employed by academic or research institutions where they drive innovation across a wide range of medical specialties and may also use their extensive training to focus their clinical practices on specialized patient populations, such as those with rare genetic diseases or cancers. Although they are a minority of both practicing physicians and active research scientists, physician-scientists are often cited as playing a critical roles in translational medicine and clinical research by adapting biomedical research findings to health care applications. Over time, the term physi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pancreatic Cancer
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known. The most common, pancreatic adenocarcinoma, accounts for about 90% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type. These adenocarcinomas start within the part of the pancreas that makes digestive enzymes. Several other types of cancer, which collectively represent the majority of the non-adenocarcinomas, can also arise from these cells. About 1–2% of cases of pancreatic cancer are neuroendocrine tumors, which arise from the hormone-producing cells of the pancreas. These are generally less aggressive than pancreatic adenocarcinoma. Signs and symptoms of the most-common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Agilent Technologies
Agilent Technologies, Inc. is an American life sciences company that provides instruments, software, services, and consumables for the entire laboratory workflow. Its global headquarters is located in Santa Clara, California. Agilent was established in 1999 as a spin-off from Hewlett-Packard. The resulting IPO of Agilent stock was the largest in the history of Silicon Valley at the time. Agilent focuses its products and services on six markets: food, environmental and forensics, pharmaceutical, diagnostics, chemicals and advanced materials, and research. From 1999 to 2014, the company also produced test and measurement equipment for electronics; that division was spun off to form Keysight. Products and services Agilent serves analytical laboratories and the clinical and routine diagnostics markets with a full suite of technology platforms. These include: automation, bioreagents, FISH probes, gas and liquid chromatography, immunohistochemistry, informatics, mass spectr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Learning Health Systems
Learning health systems (LHS) are health and healthcare systems in which knowledge generation processes are embedded in daily practice to improve individual and population health. At its most fundamental level, a learning health system applies a conceptual approach wherein science, informatics, incentives, and culture are aligned to support continuous improvement, innovation, and equity, and seamlessly embed knowledge and best practices into care delivery The idea was first conceptualized in a 2006 workshop organized by the US Institute of Medicine (now the National Academy of Medicine (NAM)), building on ideas around evidence-based medicine and "practice-based evidence". and around recognition of the persistent gap between evidence generated in the context of biomedical research and the application of that evidence in the provision of care. The need to close this gap was further underscored by the growth of electronic health records (EHR) and other innovations in health informati ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
The Cancer Genome Atlas
''The'' () is a grammatical article in English, denoting persons or things that are already or about to be mentioned, under discussion, implied or otherwise presumed familiar to listeners, readers, or speakers. It is the definite article in English. ''The'' is the most frequently used word in the English language; studies and analyses of texts have found it to account for seven percent of all printed English-language words. It is derived from gendered articles in Old English which combined in Middle English and now has a single form used with nouns of any gender. The word can be used with both singular and plural nouns, and with a noun that starts with any letter. This is different from many other languages, which have different forms of the definite article for different genders or numbers. Pronunciation In most dialects, "the" is pronounced as (with the voiced dental fricative followed by a schwa) when followed by a consonant sound, and as (homophone of the archaic p ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
International Cancer Genome Consortium
The International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers. The ICGC was launched in 2008 to coordinate large-scale cancer genome studies in tumours from 50 cancer types and/or subtypes that are of main importance across the globe. Systematic studies of more than 25,000 cancer genomes at the genomic, epigenomic and transcriptomic levels will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies. The ICGC incorporates data from The Cancer Genome Atlas (TCGA) and the Sanger Cancer Genome Project. Professor Andrew Biankin AO, Regius Professor and Director of the Wolfson Wohl Cancer Research Centre at the University of Glasgow has been Executive Director and Chairman from 2018. Goals The ICGC ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
.jpeg/1200px-Space_Aggressors_test_Red_Flag_Airmen_(2743147).jpeg "Click for more on -> Agilent Technologies")
.png "Click for more on -> The Cancer Genome Atlas")